In Simple Terms
A large study in Hong Kong found that people taking some common medicines for weak bones were diagnosed with dementia less often than certain other patients. But the study only found a connection; it did not prove the medicines caused the difference. These drugs should not be taken to prevent dementia, and more research is needed to find out whether they might help the brain.
Why This Connection Is Worth a Closer Look
A medicine prescribed to strengthen bones may matter for more than the skeleton. In an analysis of health records from more than 120,000 patients, one group of osteoporosis treatments was linked to a lower chance of a dementia diagnosis than taking no bone medication—and an even lower chance than with some other bone drugs. The finding is striking, but it does not show that these treatments prevent Alzheimer’s disease or dementia. It is a lead that needs to be tested in studies designed to answer that question directly.
Dementia is not a single disease. The term describes a group of conditions that gradually affect memory, thinking, and the ability to manage everyday activities. Alzheimer’s disease is one of the best-known conditions associated with dementia. More than 55 million people worldwide are living with dementia, and estimates cited in the study suggest that number could reach 139 million by 2050. The World Health Organization has identified dementia as a global health priority.
Newer treatments can slow the decline associated with some cases of Alzheimer’s disease and related dementia, but they are not an easy option for everyone. Their high cost, limited suitability for some patients, and continuing questions about how much they help all make the search for other options important. One avenue researchers are exploring is whether medicines already in use might have benefits beyond the conditions they were originally developed to treat.
That interest does not mean every older drug will become a dementia treatment, or that a connection seen in health records is enough to change medical practice. It can, however, help researchers identify promising questions to test—especially when patients are already taking a medicine for another condition. In this study, the question was whether certain osteoporosis treatments were also linked to a lower chance of dementia.
Bones and the Brain in Later Life
Osteoporosis weakens bone tissue and makes bones more likely to break, sometimes after a relatively minor injury. Dementia affects thinking, memory, and the ability to manage everyday life. Although the two conditions affect different parts of the body and are not the same kind of illness, they can occur in the same person. They also share risk factors, including older age, being female, and low levels of physical activity.
In earlier research, a team at the University of Hong Kong reported that osteoporosis and fractures were independently associated with a higher risk of dementia. The team also observed that people with dementia were more likely to fall and break bones. In everyday health, the relationship may work in both directions: weak bones raise the burden of fractures, while problems with movement or balance associated with dementia may make falls more likely. This pattern does not prove that either condition causes the other in every case.
That raised a question worth investigating: if a medicine slows bone loss and reduces the risk of fractures, might it also be linked to better brain health? The study does not explain the biological mechanism behind that possibility, nor does it show that improving bone health automatically protects memory. Instead, it compares what happened to groups of patients in healthcare records and looks for differences that warrant more rigorous testing.
Which Medicines Did Patients Take?
The researchers focused on a group of drugs known as nitrogen-containing bisphosphonates, or NBPs. Examples include alendronate and zoledronate, both commonly used to treat osteoporosis. Their main role is to slow the breakdown of bone tissue, helping preserve bone strength and reduce the chance of fractures.
Interest in these drugs does not mean their effects on the brain are known or established. Earlier scientific observations prompted questions about whether some processes affected by the medicines might overlap with processes involved in the development of Alzheimer’s disease and other forms of dementia. That possible overlap provides a starting point for research, not evidence that the drugs can prevent a neurological disease or directly affect brain cells.
The appeal of repurposing an existing medicine is that its use for bone disease is already well established, making it easier to investigate possible additional benefits than to start from scratch with a completely new compound. But long experience using a drug for osteoporosis does not establish that it is safe or effective for a different purpose. Any new use would need evidence of its own and a medical decision tailored to each patient.
What Did the Records of 120,000 Patients Show?
The study was conducted by researchers in the Department of Pharmacology and Pharmacy at the Li Ka Shing Faculty of Medicine, The University of Hong Kong, commonly known as HKUMed. The team analyzed electronic medical records from across Hong Kong covering more than 120,000 patients aged 60 or older. All had osteoporosis or had previously experienced a fragility fracture—a break that can happen after a minor injury when bones are weak.
The records covered the period from 2005 to 2020. They allowed the researchers to compare the risk of an Alzheimer’s disease or related dementia diagnosis among people who used nitrogen-containing bisphosphonates with the risk among patients who received no osteoporosis medication and patients who used other types of bone drugs.
In the first comparison, the risk of dementia was 16% lower among people taking these bisphosphonates than among patients who had not received drug treatment for osteoporosis. The difference was larger when they were compared with patients taking other bone treatments: use of nitrogen-containing bisphosphonates was associated with a 24% lower risk.
These percentages describe differences observed between the groups; they do not mean the drugs provide certain protection to every person or reduce each individual’s chance of dementia by the same amount. The comparison group also matters. The 16% figure comes from comparing bisphosphonate users with people who took no bone medication, while the 24% figure comes from comparing them with people who used other bone treatments. Each number should be understood in the context of the comparison that produced it.
Signals Among Women and After Hip Fractures
The analysis suggested that the link between treatment and lower dementia risk was stronger among women and among patients who had experienced hip fractures. The results do not offer a definitive explanation for why this pattern appeared in those groups, nor do they prove that the medicines have different biological effects in those patients. It is a secondary finding from patient records that may help researchers decide which groups to study more closely.
Hip fractures are especially relevant in this context because they are a serious injury for older patients and fit the study’s broader focus on osteoporosis and fractures. But it would be wrong to conclude that taking bisphosphonates after a hip fracture prevents dementia, or that women should take them for that purpose. Independent analyses and further studies are needed to determine whether these differences are real and can be reproduced.
Any analysis of health records may be affected by factors that researchers cannot fully control. People who receive a particular treatment may differ from others in their health, the medical follow-up they receive, or other factors that were not adequately recorded. For that reason, even a comparison involving a large number of participants cannot provide the same kind of evidence as a clinical trial designed to test the treatment’s effects.
What Does One Case per 48 Patients Mean?
The researchers estimated that treating 48 patients with nitrogen-containing bisphosphonates for five years might be associated with one fewer case of dementia. This estimate is based on the study’s results; it is not a promise that treating every group of 48 people will prevent one case. Nor does it prove that taking the medicine caused the difference seen in the records.
The meaning of this figure depends on a question the study could not settle: did the drugs themselves account for the lower risk, or did differences between patients and other factors contribute to the result? If future research confirms a direct effect, it will be important to understand how large the benefit really is, who might benefit, and how it compares with the risks of treatment. Until then, the estimate is a reason to investigate—not a basis for changing patients’ prescriptions.
An Observational Study Does Not Prove Prevention
The research team emphasized that this was an observational study. The researchers reviewed what had happened in medical records and compared patients who received different treatments; they did not randomly assign patients to the drug or a placebo to test whether it prevented dementia. The results therefore show an association between use of a group of medicines and lower risk in the study groups, but they do not establish cause and effect.
This distinction is essential when reading medical news. Saying a treatment was associated with lower risk describes what the data showed; saying it prevents dementia goes beyond what this study can prove. Observational research can uncover important signals, but it cannot by itself rule out the possibility that other factors explain some of the association. Nor can it establish that taking the medicine will change the course of disease for any particular person.
So anyone hoping to protect their memory should not start taking these drugs on their own, and patients with osteoporosis should not stop a prescribed treatment because of an exaggerated reading of the findings. Decisions about bone medicines belong with the doctor, who can weigh the need for treatment, its benefits, and its risks for each patient. This study alone does not support using these medicines to prevent dementia.
The Next Step: Test the Idea Directly
The study was published in the journal Alzheimer’s & Dementia and led by Professor Cheung Ching-long of HKUMed’s Department of Pharmacology and Pharmacy. Dr. Sing Chor-wing was the first author. Professor Chan Kwun-ho, Dr. Patrick Chiu Ka-chun, and Professor Catherine Tan Chun-ping, from the university’s Department of Medicine in the School of Clinical Medicine, also took part.
The researchers say the findings provide a practical starting point for further work on whether these medicines might offer a benefit to the brain as well as the bones. To move from an observed association to a more certain answer, future studies must test whether the treatment itself lowers the risk of cognitive decline and whether any effect holds across different groups of patients. Research should also clearly distinguish between drug types, treatment duration, and the health outcomes being measured.
This line of research matters as the number of people with dementia grows with an aging population, while newer treatments remain expensive or unsuitable for some people. If a medicine already used by people who need it for bone health is eventually shown to provide an additional benefit, that could have practical value. But the path from a finding in health records to a treatment recommendation requires proof that the medicine works—not simply an observation that one group of patients had less dementia.
The Bottom Line
A Hong Kong study points to an intriguing possibility: nitrogen-containing bisphosphonates, including alendronate and zoledronate, were associated with a 16% lower risk of Alzheimer’s disease or related dementia compared with taking no bone medication, and a 24% lower risk compared with using other bone treatments. The study included more than 120,000 patients aged 60 and older and examined records from 2005 to 2020. The association appeared stronger among women and people who had experienced a hip fracture.
But the findings do not prove that these drugs prevent dementia. The study was observational, and the estimate that treating 48 patients for five years might prevent one case is a possibility calculated from the data, not a treatment guarantee. The key takeaway is not that a bone medicine has become a brain treatment, but that a promising idea deserves direct testing. Until stronger evidence is available, these drugs should be used for established medical reasons and under a doctor’s guidance.